Home » PharmaFrontiers Selects INC Research as Development Partner
PharmaFrontiers Selects INC Research as Development Partner
PharmaFrontiers a biotechnology company developing autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes, and INC Research, a global contract research organization (CRO) specialized in central nervous system (CNS), oncology, and pediatric clinical research, recently announced that they have formed a strategic relationship to develop multiple sclerosis therapies.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050503005277&newsLang=en)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May